167
Participants
Start Date
October 31, 2011
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
SAR245409
Pharmaceutical form:capsule Route of administration: oral
Investigational Site Number 056003, Brussels
Investigational Site Number 036005, Kingswood
Investigational Site Number 056001, Leuven
Investigational Site Number 036002, Clayton
Investigational Site Number 036003, Perth
Investigational Site Number 036001, Hobart
Investigational Site Number 056002, Ghent
Investigational Site Number 840001, Philadelphia
Investigational Site Number 840002, Morgantown
Investigational Site Number 840006, Augusta
Investigational Site Number 840104, Fort Meyers
Investigational Site Number 250002, Montpellier
Investigational Site Number 250004, Rennes
Investigational Site Number 840013, Lexington
Investigational Site Number 840007, Paducah
Investigational Site Number 840014, Canton
Investigational Site Number 840011, Maywood
Investigational Site Number 276003, Frankfurt am Main
Investigational Site Number 840015, St Louis
Investigational Site Number 250001, Pierre-Bénite
Investigational Site Number 250005, Rouen
Investigational Site Number 276001, Ulm
Investigational Site Number 840012, Los Angeles
Investigational Site Number 250003, Villejuif
Investigational Site Number 840010, Kansas City
Investigational Site Number 840004, Boston
Investigational Site Number 276002, Jena
Investigational Site Number 528001, Amsterdam
Investigational Site Number 528003, Groningen
Investigational Site Number 528002, Rotterdam
Lead Sponsor
Sanofi
INDUSTRY